{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:07:15Z","timestamp":1784837235838,"version":"3.55.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oral gabapentin is approved as an anticonvulsant medication and to treat postherpetic neuralgia. Its nonopioid properties and presumed spinal site of analgesic action made the study on intrathecal gabapentin attractive to establish the minimum effective dose for a later, pivotal trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The authors examined the safety and efficacy of intrathecal gabapentin in a randomized, blinded, placebo-controlled, multicenter trial in a heterogeneous cohort of candidates with chronic pain for intrathecal drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients (N = 170) were randomized to receive continuous intrathecal gabapentin (0 [placebo], 1, 6, or 30\u2009mg\/day) during 22 days of blinded treatment after implantation of a permanent drug delivery system. The highest dose, 30\u2009mg\/day, was selected to maintain a safety margin below the 100-mg\/day dose that was explored in a phase 1 study. The authors found no statistically significant difference in the primary outcome measure, which was the numerical pain rating scale and response rate after 3 weeks, for any dose\n                      <jats:italic toggle=\"yes\">versus<\/jats:italic>\n                      placebo. Physical functioning, quality of life, and emotional functioning also revealed no differences. Small, nonsignificant changes occurred in opioid medication use. The most frequent device-related adverse events were transient postimplant (lumbar puncture) headache, pain, and nausea. The most frequent gabapentin-related adverse events were nausea, somnolence, headache, dizziness, fatigue, and peripheral edema.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Twenty-two days of intrathecal gabapentin did not demonstrate statistically significant or clinically meaningful analgesic effects. The study sponsor has no current plans for further studies. Drug-related adverse events were similar to those for oral gabapentin. Most device-related adverse events resulted from the implant surgery or anesthesia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aln.0b013e3182a10fbf","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T14:35:53Z","timestamp":1372948553000},"page":"675-686","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Intrathecal Gabapentin to Treat Chronic Intractable Noncancer Pain"],"prefix":"10.1097","volume":"119","author":[{"given":"Richard","family":"Rauck","sequence":"first","affiliation":[{"name":"Center for Clinical Research, LLC, Carolinas Pain Institute PA, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Coffey","sequence":"additional","affiliation":[{"name":"Medtronic, Inc., Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Medical Pain Clinics, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Professor, Department of Anesthesiology, University of California San Diego Medical Center, Pain Medicine, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn R.","family":"Webster","sequence":"additional","affiliation":[{"name":"Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally E.","family":"McCarville","sequence":"additional","affiliation":[{"name":"Medtronic, Inc., Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Grigsby","sequence":"additional","affiliation":[{"name":"Napa Pain Institute, Napa, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Page","sequence":"additional","affiliation":[{"name":"Medtronic, Inc., Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20241223","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.","volume":"61","year":"1995","journal-title":"Pain"},{"key":"R3-20241223","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archneur.60.11.1524","article-title":"Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations.","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"key":"R5-20241223","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/pgmj.57.663.16","article-title":"Long-term treatment of trigeminal neuralgia with carbamazepine.","volume":"57","year":"1981","journal-title":"Postgrad Med J"},{"issue":"suppl 1","key":"R6-20241223","first-page":"S39","article-title":"Mechanisms of action of gabapentin.","volume":"153","year":"1997","journal-title":"Rev Neurol (Paris)"},{"key":"R7-20241223","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/00000542-200004000-00031","article-title":"Antiallodynic effect of intrathecal gabapentin and its interaction with clonidine in a rat model of postoperative pain.","volume":"92","year":"2000","journal-title":"Anesthesiology"},{"key":"R8-20241223","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3346\/jkms.2002.17.2.225","article-title":"The effect of intrathecal gabapentin on mechanical and thermal hyperalgesia in neuropathic rats induced by spinal nerve ligation.","volume":"17","year":"2002","journal-title":"J Korean Med Sci"},{"key":"R9-20241223","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","article-title":"The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel.","volume":"271","year":"1996","journal-title":"J Biol Chem"},{"key":"R10-20241223","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1098-7339(06)80010-6","article-title":"Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat.","volume":"22","year":"1997","journal-title":"Reg Anesth"},{"key":"R11-20241223","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1213\/00000539-199802000-00025","article-title":"The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat.","volume":"86","year":"1998","journal-title":"Anesth Analg"},{"key":"R12-20241223","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.","volume":"302","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-20241223","first-page":"214","article-title":"Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats.","volume":"290","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-20241223","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1124\/jpet.102.041574","article-title":"Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin.","volume":"303","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20241223","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1124\/mol.59.5.1243","article-title":"Calcium channel \u03b1(2)\u03b4 subunits-structure and gabapentin binding.","volume":"59","year":"2001","journal-title":"Mol Pharmacol"},{"key":"R16-20241223","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00000542-199801000-00028","article-title":"Characterization of the effects of gabapentin and 3-isobutyl-gamma-aminobutyric acid on substance P-induced thermal hyperalgesia.","volume":"88","year":"1998","journal-title":"Anesthesiology"},{"key":"R17-20241223","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A summary of mechanistic hypotheses of gabapentin pharmacology.","volume":"29","year":"1998","journal-title":"Epilepsy Res"},{"key":"R18-20241223","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1213\/00000539-199908000-00034","article-title":"The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat.","volume":"89","year":"1999","journal-title":"Anesth Analg"},{"key":"R19-20241223","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/ALN.0b013e318254e6fd","article-title":"Gabapentin inhibits \u03b3-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats.","volume":"116","year":"2012","journal-title":"Anesthesiology"},{"key":"R20-20241223","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa042580","article-title":"Morphine, gabapentin, or their combination for neuropathic pain.","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"R21-20241223","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJMc1000964","article-title":"Reporting of trials of cabapentin (Letter).","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"R22-20241223","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJMe058039","article-title":"Combination therapy for neuropathic pain\u2014Which drugs, which combination, which patients?","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"R23-20241223","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use.","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"R24-20241223","first-page":"209","article-title":"Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin.","volume":"17","year":"1989","journal-title":"Adv Epileptology"},{"key":"R25-20241223","first-page":"613","article-title":"Clinical pharmacokinetics of gabapentin.","volume":"31","year":"1995","journal-title":"Drugs Today"},{"key":"R26-20241223","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0920-1211(92)90020-T","article-title":"Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin.","volume":"11","year":"1992","journal-title":"Epilepsy Res"},{"key":"R27-20241223","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.","volume":"113","year":"2005","journal-title":"Pain"},{"key":"R28-20241223","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.","volume":"40","year":"2000","journal-title":"Epilepsy Res"},{"key":"R29-20241223","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":"A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma.","volume":"10","year":"1993","journal-title":"Pharm Res"},{"key":"R30-20241223","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pain.2010.02.018","article-title":"Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations.","volume":"149","year":"2010","journal-title":"Pain"},{"key":"R31-20241223","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1212\/01.wnl.0000275528.01263.6c","article-title":"Clinical trial outcome in neuropathic pain: Relationship to study characteristics.","volume":"70","year":"2008","journal-title":"Neurology"},{"key":"R32-20241223","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0197-2456(86)90034-6","article-title":"Analysis of data from multiclinic trials.","volume":"7","year":"1986","journal-title":"Control Clin Trials"},{"key":"R33-20241223","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing.","volume":"9","year":"1990","journal-title":"Stat Med"},{"key":"R34-20241223","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2528930","article-title":"A test for differences between treatment means when several dose levels are compared with a zero dose control.","volume":"27","year":"1971","journal-title":"Biometrics"},{"key":"R35-20241223","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2307\/2556164","article-title":"The comparison of several dose levels with a zero dose control.","volume":"28","year":"1972","journal-title":"Biometrics"},{"key":"R36-20241223","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression.","volume":"4","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"R37-20241223","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1526-4637.2001.01041.x","article-title":"Designing pain research from the patient\u2019s perspective: What trial end points are important to patients with chronic pain?","volume":"2","year":"2001","journal-title":"Pain Med"},{"key":"R38-20241223","first-page":"129","article-title":"Pain assessment: Global use of the Brief Pain Inventory.","volume":"23","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"R40-20241223","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1525-1403.2007.00128.x","article-title":"Polyanalgesic consensus conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel.","volume":"10","year":"2007","journal-title":"Neuromodulation"}],"container-title":["Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.asahq.org\/anesthesiology\/article-pdf\/119\/3\/675\/262709\/20130900_0-00027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/anesthesiology.pubs.asahq.org\/article.aspx?volume=119&page=675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:25:14Z","timestamp":1784834714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/ALN.0b013e3182a10fbf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/aln.0b013e3182a10fbf","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718028222.793483495","asserted-by":"object"}]},"ISSN":["0003-3022"],"issn-type":[{"value":"0003-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}